



The authors examined 501 genes respon-
sible for the 560 genodermatoses defined 
by a unique OMIM entry. The mismatch is 
attributable to the possibility that a single 
gene can cause more than one disease 
(allelic variants and pleiotropy) and, con-
versely, a single disease can be caused 
by different genes (phenocopies and 
genetic heterogeneity). Genes operate 
within intricate pathways and networks, 
many of which are known. The authors 
use existing software to map these 501 
genes onto these known networks, high-
lighting nodes and groups of disorders. 
This exercise does not take into account 
variation caused by type of mutation, let 
alone epigenetic factors. Nonetheless, 
the authors demonstrate overlapping 
networks of genes—for example, those 
causing depigmentation, deafness, or 
both—and this process will undoubtedly 
reveal new candidate genes for disorders 
of unknown cause. This type of analysis 
could be applied to the 1-2-3-4 ecto-
dermal dysplasia classification now that 
several ectodermal dysplasia genes and 
pathways are known.
Where does this take us?
Despite some intrinsic limitations and 
simplifications, this analytical approach 
may help researchers identify candidate 
disorders and genes for future study. 
CGenDerm can be improved and extend-
ed in the future. It might be adapted to form 
a searchable database to aid clinicians. It 
remains to be seen whether the analyti-
cal methods will tell us more than existing 
search engines and Sherlockian deduc-
tion—a process that works only because 
the author already knows the answer.
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Stromal Collagenase in Melanoma:  
A Vascular Connection
Veli-Matti Kähäri1 and Risto Ala-aho1
In this issue, Zigrino et al. report on the role of host-derived mouse collagenase-3 
(matrix metalloproteinase (MMP)-13) in melanoma growth and metastasis using a 
mouse model that lacks MMP-13. The authors demonstrate that vascularization of 
cutaneous melanomas in these mice is impaired compared with that of controls. 
This study emphasizes the importance of stromal murine MMP-13, a functional 
homologue of human MMP-1, in tumor progression.
Journal of Investigative Dermatology (2009) 129, 2545–2547. doi:10.1038/jid.2009.298
Proteinases in tumor growth
Tumor progression is a multistage pro-
cess in which malignant cells invade 
surrounding tissue and metastasize to dis-
tant organs. An important stage of tumor 
invasion is the loss of an intact basement 
membrane. Subsequently, malignant 
cells metastasize to other organs by 
invading blood or lymphatic vessels. 
Tumor cells then enter blood or lymph 
circulation, attach at a distant location, 
and degrade the basement membranes 
and extracellular matrix (ECM) at the 
sites of metastases. Furthermore, angio-
genesis is required for tumor growth, and 
tumor-induced lymphangiogenesis plays 
an important role in tumor metastasis 
(Karpanen and Alitalo, 2008).
collagenases
Collagenase-1 (matrix metalloproteinase 
(MMP)-1), collagenase-2 (MMP-8), and 
collagenase-3 (MMP-13) are principal 
secreted proteinases capable of cleaving 
native fibrillar collagens of types I, II, III, 
V, and IX. In addition to MMP-1, MMP-8, 
and MMP-13, gelatinase-A (MMP-2) has 
a weak catalytic activity toward fibrillar 
collagens (Ala-aho and Kähäri, 2005). 
Furthermore, membrane-type-1 MMP 
(MMP-14) cleaves fibrillar collagens. 
Collagenases vary in their ability to cata-
lyze fibrillar collagens.
The first MMP to be identified, a col-
lagenase, was purified from the tails of 
tadpoles by Gross and Lapière (1962). 
The first human MMP to be identified, 
MMP-1, was cloned from adult skin fibro-
blasts (Goldberg et al., 1986). Human 
MMP-1 is expressed in physio logical pro-
cesses, for example, during embryonic 
development and wound healing, as well 
as under a number of pathological condi-
tions, including chronic cutaneous ulcers 
and various malignant tumors. MMP-1 
is expressed by a variety of normal cells 
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in culture, including keratinocytes, fibro-
blasts, endothelial cells, monocytes, and 
macrophages, as well as by several types 
of tumor-derived cells.
Two closely related mouse coun-
terparts of human MMP-1 have been 
identified: Mcol1-A and Mcol1-B. Both 
are expressed during embryo implan-
tation, but only Mcol-A cleaves fibril-
lar collagens (Balbin et al., 2001). The 
original murine interstitial collagenase 
(MMP-13) exhibits the highest homol-
ogy with human MMP-13, indicating 
that it represents a counterpart to human 
MMP-13. Notably, mouse MMP-13 
and human MMP-1 are expressed in 
similar situations—evidence that mouse 
MMP-13 is also a functional homologue 
of human MMP-1.
MMP-8 is stored in secretory gran-
ules of neutrophils and released in 
response to extracellular stimuli. MMP-8 
is also expressed by chondrocytes and 
mononuclear fibroblast-like cells in 
rheumatoid synovium and in bronchial 
epithelial cells and monocytes during 
bronchitis. MMP-8 can regulate inflam-
mation by cleaving and activating 
lipopolysaccharide-induced CXC chemo-
kine LIX-1, a potent chemoattractant for 
monocytes and activator of neutrophil 
functions (Balbin et al., 2003).
Collagenase-3 (MMP-13) was origi-
nally cloned from human breast cancer. 
Compared with other MMPs, MMP-13 
has wide substrate specificity. It can 
inactivate chemokines such as mono-
cyte chemoattractant protein-3 and 
stromal cell-derived factor-1, and it also 
appears to be involved in the activation 
of proTGF-β3. Expression of MMP-13 is 
limited to a few physiologic situations 
that involve rapid and effective remodel-
ing of collagenous ECM (fetal bone devel-
opment, postnatal bone remodeling, and 
gingival and fetal skin wound repair, for 
example). Mice lacking MMP-13 exhibit 
delayed formation of long bones, evi-
dence for the role of MMP-13 in skel-
etal development (Inada et al., 2004). In 
humans, MMP-13 expression is detected 
under pathological conditions character-
ized by the destruction of normal tissue 
architecture, such as osteoarthritic carti-
lage, rheumatoid synovium, and chronic 
cutaneous ulcers (Vaalamo et al., 1997).
collagenases in cancer progression
It is accepted that collagenases play a 
role in the initial cleavage of fibrillar col-
lagens of types I, II, and III, and it has 
been suggested that degradation of col-
lagenous ECM by these MMPs is impor-
tant for tumor invasion. Numerous stud-
ies have demonstrated overexpression 
of collagenases in malignant tumors as 
compared with normal tissues, suggest-
ing a role for collagenases in cancer cell 
invasion. Beside malignant cells, stromal 
fibroblasts, vascular endothelial cells, 
and inflammatory cells produce MMPs, 
which contribute to proteolytic remod-
eling of the peritumoral ECM. However, 
there is little direct evidence to character-
ize the role of distinct collagenases in dif-
ferent stages of tumor progression.
MMP-1 is expressed by tumor cells or 
adjacent stromal fibroblasts in response 
to stimulating factors produced by 
tumor cells. In both cases, MMP-1 is 
expressed at sites of tumor invasion. 
Overexpression of MMP-1 has been 
demonstrated in a variety of cancers, 
and its expression is associated with 
poor prognosis in colorectal, gastric, 
and esophageal carc inomas, metastatic 
melanoma, and pancreatic adenocarci-
noma. In head-and-neck squamous-cell 
carcinomas (SCCs), MMP-1 expression 
is often localized to stromal cells sur-
rounding tumor islands.
MMP-8 is expressed mainly by neu-
trophils in inflammatory reactions, but 
it is also detected in certain malignant 
tumors, including head-and-neck SCCs 
and ovarian cancer. MMP-8 might play 
a dual role in tumor progression because 
the incidence of chemically induced 
skin carcinomas is increased in MMP-8-
deficient male mice (Balbin et al., 2003).
The expression of MMP-13 has been 
detected in invasive malignant tumors, 
including breast carcinomas, SCCs of the 
head and neck (Johansson et al., 1997), 
SCCs of the skin (Airola et al., 1997), and 
primary and metastatic melanoma (Airola 
et al., 1999). MMP-13 is not expressed by 
normal epidermal keratinocytes in culture 
or in vivo in intact skin or during wound 
repair (Vaalamo et al., 1997). Therefore, 
MMP-13 expression appears to be a 
marker for squamous epithelial cell trans-
formation. MMP-13 expression is detect-
ed mainly in tumor cells at the invading 
front of SCCs, but it is also expressed by 
stromal fibroblasts surrounding tumor 
cells. MMP-13 expression in SCCs corre-
lates with a tumor’s capacity for invasion 
and metastasis, suggesting that MMP-13 
expression levels could be an indica-
tor for the invasive capacity of SCCs. 
Accordingly, the growth of cutaneous 
SCCs was found to be potently suppressed 
by MMP-13 targeted antisense ribozyme 
(Ala-aho et al., 2004).
collagenases in angiogenesis
In this issue, Zigrino et al. study the 
role of stromal mouse MMP-13 in 
melanoma growth using a mouse model 
lacking MMP-13. In this model, the 
growth of tumors established by intra-
dermally injected melanoma cells was 
significantly impaired, especially at the 
early stage of tumor growth, compared 
with that of wild-type mice. Interestingly, 
the metastasis rate of cutaneous mela-
nomas was also reduced, especially the 
development of metastasis in the heart. 
The authors demonstrate that vascu-
larization of melanomas in MMP-13-
deficient mice is impaired compared 
with that of wild-type mice, providing a 
possible explanation for impaired tumor 
growth and metastasis. These findings 
are consistent with their observation of 
murine MMP-13 expression in vascu-
lar endothelial cells and macrophages 
within the stromal compartment of the 
tumors. This expression pattern is simi-
lar to that of human MMP-1, provid-
ing evidence that in this model murine 
MMP-13 functions as a homologue of 
human MMP-1 (Airola et al., 1999).
The results reported in this issue by 
Zigrino et al. provide direct evidence 
that murine MMP-13 plays an impor-
tant role in new blood vessel formation 
during melanoma growth. Recent stud-
ies have identified a novel mechanism 
by which MMP-1 promotes angiogen-
esis. MMP-1 proteolytically activates 
protease activated receptor-1 (PAR1), 
a thrombin receptor that is highly 




expressed in endothelial cells (Blackburn 
and Brinckerhoff, 2008). It appears 
that MMP-1 can act directly on endo-
thelial cells as a proangiogenic signaling 
molecule to complement the effect of 
thrombin in promoting angiogenesis and 
tumor progression. Interestingly, it has 
also been shown in a breast cancer model 
that stromal fibroblast-derived MMP-1 in 
the tumor microenvironment can alter 
the behavior of tumor cells through PAR1 
by promoting cell migration and invasion 
(Boire et al., 2005). These results comple-
ment previous findings that expression of 
MMP-1 serves as a marker for rapid pro-
gression in human metastatic melanoma 
(Nikkola et al., 2002, 2005).
Since the initial identification of 
collagenase in tadpoles by Gross and 
Lapière (1962), it has become evident 
that the role of collagenases is more 
complex than that of simply promoting 
turnover of collagenous ECM. MMPs 
can proteolytically activate and release 
biologically active fragments from ECM, 
and they can also process several non-
matrix substrates embedded in the ECM 
or on the cell surface. The results of 
Zigrino et al. provide direct evidence 
that host-derived collagenases play an 
important role in tumor progression 
and that novel inhibition strategies for 
stromal collagenases may be an impor-
tant approach for targeting vasculariza-
tion of invasive malignant tumors.
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Cancer Risk Evaluation in Psoriasis:  
In Search of the Holy Grail?
Carle F. Paul1,2 and Pierre-Antoine Gourraud3
Benefit–risk assessment of systemic treatment in psoriasis is a dynamic process. 
Long-term safety of psoriasis therapies has been questioned, with the spectrum of 
systemic immunosuppression potentially leading to increased cancer risk. In this 
issue, Brauchli et al. report on a population-based analysis of cancer risk in a large 
cohort of psoriasis patients, most of whom had not been treated with systemic 
agents. The study prepares the ground for future prospective long-term cohort stud-
ies in psoriasis patients treated with systemic therapies, including biological agents.
Journal of Investigative Dermatology (2009) 129, 2547–2549. doi:10.1038/jid.2009.203
The association between psoriasis and 
cancer risk has received considerable 
attention, as has the role of certain thera-
peutic agents used to treat psoriasis in 
promoting cancer risk. Prospective cohort 
studies have demonstrated that the risk 
of nonmelanoma skin cancer increases 
linearly with the number of psoralen 
plus ultraviolet light A (PUVA) sessions 
in patients with psoriasis (Nijsten and 
Stern, 2003). In addition, treatment with 
systemic immunosuppressant agents in 
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